Blog
RSS FeedPosted by Michael Wonder on 13 Feb 2017
SMC - February 2017 decisions
13 February 2017 - Treatments for cancer, cholesterol and chronic migraines among medicines accepted for routine use by NHS Scotland. ...
Posted by Michael Wonder on 13 Feb 2017
Outcomes from the November 2016 PTAC meeting
13 February 2017 - PHARMAC has published the minutes from the 3-4 November meeting. ...
Posted by Michael Wonder on 13 Feb 2017
NICE approves Incyte’s leukaemia drug for routine NHS use
13 February 2017 - NICE published draft guidance recommending ponatinib (Iclusig) for routine use on the NHS, to treat some ...
Posted by Michael Wonder on 12 Feb 2017
TGA approval timelines for new cancer medicines
13 February 2017 - The publication of submission dates in the TGA's Annual Report for 2016 enables more insightful analysis ...
Posted by Michael Wonder on 10 Feb 2017
Decision to maintain full subsidy for gefitinib (Iressa) from 1 April 2017
10 February 2017 - PHARMAC is pleased to announce the approval of a proposal to maintain full subsidy for gefitinib ...
Posted by Michael Wonder on 09 Feb 2017
FDA approves drug to treat Duchenne muscular dystrophy
9 February 2017 - The U.S. FDA today approved Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 ...
Posted by Michael Wonder on 09 Feb 2017
FDA approves Bio Products Laboratory's Gammaplex 10% for treatment of primary immunodeficiency and chronic immune thrombocytopenic purpura
8 February 2017 - Bio Products Laboratory today announced that the U.S. FDA has approved Gammaplex 10% (immune globulin intravenous ...
Posted by Michael Wonder on 08 Feb 2017
Lilly's Trulicity (dulaglutide) label updated to include use in combination with basal insulin for adults with type 2 diabetes
8 February 2017 - The label for Eli Lilly and Company's once-weekly Trulicity (dulaglutide) is now updated to include use ...
Posted by Michael Wonder on 08 Feb 2017
FDA approves Amgen's Parsabiv (etelcalcetide), first new treatment in more than a decade for secondary hyperparathyroidism in adult patients on hemodialysis
7 February 2017 - Intravenous administration puts delivery in hands of health care provider. ...
Posted by Michael Wonder on 08 Feb 2017
Decision relating to nicotine replacement therapy RFP
8 February 2017 - PHARMAC has decided to not accept any proposal in response to, and to terminate the process ...
Posted by Michael Wonder on 08 Feb 2017
Health Canada approves Gazyva for patients with previously treated follicular lymphoma
7 February 2017 - Roche Canada today announced that Health Canada has approved Gazyva (obinutuzumab) in combination with bendamustine followed ...
Posted by Michael Wonder on 07 Feb 2017
Alexion 'extremely disappointed' with NICE ruling on costly Strensiq
7 February 2017 - Once again, the U.K.’s drug cost watchdogs are catching flak from the industry after issuing a ...
Posted by Michael Wonder on 07 Feb 2017
Updated PBAC outcomes for November 2016
7 February 2017 - Subsequent to the deferral at the November 2016 PBAC meeting, the PBAC recommended the PBS listing of ...
Posted by Michael Wonder on 06 Feb 2017
Cystic fibrosis sufferers to get lifesaving medication for free after government intervention
6 February 2017 - A life changing drug — previously unaffordable for Australia’s littlest cystic fibrosis sufferers costing $300,000 a ...
Posted by Michael Wonder on 06 Feb 2017
Charleston Laboratories and Daiichi Sankyo receive complete response letter from FDA for new drug application for CL-108 (hydrocodone, acetaminophen, promethazine) tablets for oral use
3 February 2017 - Charleston Laboratories and Daiichi Sankyo confirmed today that the U.S. FDA has issued a complete response ...